Benitec Biopharma Inc.
BNTCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. With a market capitalization of $439.0M, it sits in small-cap territory. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Market Cap
$439.0M
Beta
0.25
P/E (TTM)
—
P/E (Fwd)
-1.36
EPS (TTM)
$-0.94
EPS (Fwd)
$-9.42
ROE
-29.6%
ROA
-19.9%
Cash
$184.8M
Total Debt
$876,000
Free CF
-$7.1M
52W Change
15.8%
Annual Financials
Cash vs Debt
Benitec Biopharma Inc. holds $184.8M in cash against $876K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$7.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -29.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $73K (2022) to $0 (2025), a 100% decline worth watching.
The relatively low beta of 0.25 suggests BNTC is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, BNTC has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BNTC.